Why Is Revance Therapeutics (RVNC) Stock Up 86% Today?

Revance Therapeutics (NASDAQ:RVNC) stock is on the rise Monday after the biotechnology company announced a merger agreement with private skincare company Crown Laboratories. This agreement has Crown Laboratories agreeing to acquire Revance Therapeutics for $924 million. The deal is set to close by the end of 2024 and will remove RVNC stock from public trading. Crown Laboratories will acquire Revance Therapeutics by buying all outstanding shares of RVNC stock. It will pay $6.66 per share in cash for the stoc ...